NCT00752258已完成3 期
A Phase III, Multi-Center, Long-Term, Repeat-Treatment, Open-Label, Single-Arm Trial to Demonstrate the Safety of Repeat Treatment With PurTox® for the Treatment of Glabellar Rhytides ("Frown Lines")
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 576
- 试验地点
- 1
- 主要终点
- Estimation of the incidences of treatment-emergent adverse events, serious treatment-emergent adverse events, and treatment-emergent laboratory abnormalities, when PurTox is administered in repeated treatments.
研究概览
简要总结
The overall purpose of this study is to evaluate the long-term safety of repeat treatment with an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines.
详细描述
This is a Phase III, multi-center, open-label study to evaluate the long-term safety of repeat treatment with PurTox for the treatment of glabellar rhytides. Up to 576 patients will be enrolled at 12 sites in the U.S.A. and some of these patients may have participated in Mentor Purified Toxin Phase I, II and IIIa studies. Safety and tolerability of the repeat treatment with Mentor Purified Toxin will be examined during the study.
Effectiveness will be determined by the degree of frown line reduction, during maximum forced frown and at rest (neutral expression):
- as assessed live by the study doctor,
- as assessed live by the subject, and;
- as assessed by an independent reviewer based on subject photographs
Frown lines are graded on level of severity based on this scale:
Severity
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects who are 18 years of age or older with an interest in the effacement of glabellar rhytides, with or without previous Botulinum Toxin Type A exposure;
- •In good physical and mental health as determined by the investigator based on medical history, physical examination, and/or clinical laboratory tests;
- •Noticeable presence of the glabellar rhytides for a period of 6 months or longer;
- •Score at least a 2 (moderate severity) at baseline screening on the investigator's and subject's assessments (reference photographs provided) at forced frown; and
- •Capable of understanding and complying with the protocol and must have signed the informed consent document prior to performance of any study-related procedures.
排除标准
- •A history of psychiatric problems that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes;
- •A history of autoimmune disease, that, in the opinion of the investigator, might interfere with subject outcomes (e.g., osteoarthritis is not considered an exclusion criterion; however, subjects with dermatomyositis are not permitted to participate in this study);
- •A history or presence of clinically significant cardiovascular, respiratory, hepatic/biliary, renal, gastrointestinal, endocrine, or neurological disorders constituting a possible risk factor that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes;
- •Inability to substantially efface glabellar lines by manually spreading skin apart;
- •Eyelid ptosis;
- •Myasthenia gravis or diseases of neurotransmission (from medical history);
- •Current history of facial nerve paralysis;
- •Concurrent dermatologic disease of the face in the glabellar area that is deemed by the investigator to make the subject an inappropriate candidate for the study;
- •Recent flu-like syndrome that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes;
- •Neuromuscular disorder that, in the investigator's opinion, is severe enough potentially to interfere with subject outcomes;
- •Active multisystems disease that, in the investigator's opinion, might influence the outcome measures or the safety of the subject;
- •Has any condition(s) that in the investigator's opinion would a) warrant exclusion from the study, or b) prevent the subject from completing the study;
- •Currently receiving aminoglycoside antibiotic therapy, curare-like drugs, quinidine, succinylcholine, polymyxins, anticholinesterases, magnesium sulfate, or lincosamides;
- •Has taken any investigational drug during the 30 days prior to screening visit;
- •Have had dermal filler treatment to glabellar area during the 6 months prior to screening visit;
- •Female subjects who are pregnant or lactating. Female subjects who are of childbearing potential must have negative urine pregnancy test results prior to enrollment into the study. Such subjects, including peri-menopausal women who have had a menstrual period within one year, must be using appropriate birth control (see protocol/informed consent for description);
- •Unwilling or unable to comply with the protocol or to cooperate fully with the investigator and site personnel; or
- •Unable to understand verbal and/or written English or any other language in which a certified translation of the informed consent document is available.
研究组 & 干预措施
1
Experimental
Mentor Purified Toxin Botulinum Toxin Type A
干预措施: Mentor Purified Toxin Botulinum Toxin Type A (Drug)
结局指标
主要结局
Estimation of the incidences of treatment-emergent adverse events, serious treatment-emergent adverse events, and treatment-emergent laboratory abnormalities, when PurTox is administered in repeated treatments.
时间窗: Throughout
次要结局
- Estimate across treatment cycles the frequency with which subjects are responders at Day 30, based on an assessment of rhytide severity at maximum frown of 0 or 1 by the investigator(Day 30/Across all Treatment Cycles)
- Estimate across treatment cycles the frequency with which subjects are responders at Day 30, based on an assessment of rhytide severity at maximum frown of 0 or 1 by the subject(Day 30/Across treatment all cycles)
- Estimate across treatment cycles the frequency with which subjects are responders at Day 30, based on assessments of rhytide severity at maximum frown of 0 or 1 by both the investigator and the subject(Day 30/Across all treatment cycles)
- Estimate across treatment cycles the frequency with which subjects, who are responders at Day 30, based on subject assessment at maximum frown, continue to be responders at Days 90, 120, 150, and 180.(Day 30 through Day 180/Across all treatment cycles)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the EyebrowsGlabellar RhytidesFrown Lines Between the EyebrowsNCT00752050Mentor Worldwide, LLC699
已完成
3 期
Dysport® Pediatric Lower Limb Spasticity Follow-on StudyMuscle SpasticityChildrenCerebral PalsyNCT01251380Ipsen216
已完成
3 期
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)Attention-deficit/Hyperactivity DisorderNCT01081145Shire528
已完成
3 期
A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.Attention Deficit Disorder With HyperactivityNCT00246220Janssen Pharmaceutica N.V., Belgium402
已完成
3 期
Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)EpilepsyNCT01336621GlaxoSmithKline98